Cover Image
Market Research Report
Product code 
1029822

Global Autoimmune Treatment Market - 2021-2028

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Autoimmune Treatment Market - 2021-2028
Published: September 27, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • ALL
  • Description
  • Table of Contents
Description

Market Overview

The global autoimmune treatment market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

An autoimmune disorder is the disorder which occurs when the body's immune system is unable to differentiate between own cells and foreign cells due to which body mistakenly attacks normal cells. The symptoms of this disorder include abdominal pain, recurring fever, swollen glands, fatigue, and joint pain, swelling and skin problems.

Market Dynamics

The global autoimmune treatment market growth is driven by the rise prevalence of autoimmune disease coupled with growing patient awareness levels accounted for the major driver of this market.

The rising prevalence of autoimmune diseases, is expected to drive the growth in the forecast period

The major factor attributing to the growth of the autoimmune treatment market is surge in prevalence of autoimmune diseases. According to NIH (National Institutes of Health) up to 23.5 million Americans have an autoimmune disease and its prevalance is increasing. Scientists have identified 80-100 various autoimmune diseases and assume at least 40 other diseases of having an autoimmune basis. The other factors that play a major role in taking the autoimmune treatment market to the next level are increasing investments in research and development of drugs for autoimmune diseases, technological advancements in diagnosis and awareness of the therapy. Rising government initiatives for regulating these diseases is also helping the growth of the market.

Growing initiatives by the government and pharmaceutical companies expected to drive the market growth

Growing initiatives by the government and pharmaceutical companies to enhance the R&D initiatives to develop new drugs and therapies is expected to drive the market growth. The tremendous technological advancements in the field of autoimmune disorder in the last decade. For instance, phospho-specific flow cytometry technology enables the simultaneous and high-throughput examination of several phosphoepitopes within multiple cell populations, such as distinct immune compartments in the spleen or blood. This approach can facilitate a broad range of novel studies aimed at deciphering intracellular signaling events within heterogeneous populations of primary cells. These factors are driving the market growth in the forecast period.

Higher costs of the therapeutics is likely to hinder the market growth

However, higher costs of the therapeutics and low medical insurance coverage are constraining the market growth.

COVID-19 Impact Analysis

About 23.5 million Americans live with an autoimmune disease, which gives a cause to concern. Immunosuppression may increase the risk of developing COVID-19 or having a more severe case. Researchers have now found that people with rare autoimmune diseases are at a greater risk of dying at a younger age amid the Covid-19 pandemic. The results also showed that the risk of dying during Covid-19 for people with these conditions increased from age 35.

For many with autoimmune disease, immune modulating or immune suppressing medications are used to help balance an overactive or dysregulated immune system. These medications such as TNF inhibitors like Etanercept, Infliximab or Adalimumab and even steroids such as Prednisone can make individuals more susceptible to infectious diseases caused by bacteria and viruses. Besides being more susceptible to infections, individuals on immunosuppressant medications who become infected may have a more serious illness course than someone not on such a medication during the pendamic. This factor drives the growth of the market in the forecast period.

Segment Analysis

Rheumatic Disease segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

The rheumatic disease segment is expected to dominate the market owing to the rising cases of diseases. Rheumatic diseases are described by swelling that affects the connecting structures of the body, mostly the joints, sometimes the tendons, ligaments, bones, and muscles.

The therapeutics for rheumatoid disease holds the significant share and expected to remain assertive during the forecast period, due to the rising geriatric population, increasing number of pipeline drugs and the increasing cases of arthritis, fibromyalgia, systemic lupus erythematosus, gout and others, and varied range and availability of progressive therapeutics for the treatment of these diseases.

In 2018, according to RheumatoidArthritis.org, around 1.3 million Americans were affected by Rheumatoid arthritis, and the number is increasing every year, which is a driving factor for the autoimmune treatment market. The economic and social burden of these diseases is huge, without improper approaches to management and control of these diseases, the impact is expected to increase as the population grows. The increasing aging population and certain occupations which lead to injury and overuse of joints are increasing the prevalence of rheumatic disorders. The Centres for Disease Control and Prevention announced data estimating that 54.4 million U.S. adults suffer from arthritis equating to about 25% of the population. Ongoing research on new biologic therapies is anticipated to market growth.

The hospital pharmacy are expected to dominate the autoimmune treatment market during the forecast period

The hospital pharmacy held the largest share in the autoimmune treatment market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share global autoimmune treatment market

North America region is dominating the global autoimmune treatment market accounted for the largest market share in 2020. This is due to factors such as the rising incidence and prevalence of autoimmune diseases such as arthritis, lupus, multiple sclerosis, in the country. In the North America region, the United States holds the largest market share due to growing personal expenditure on healthcare. The healthcare commerce in the province is developing at a quick stride, resulting in the progress of the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.

Competitive Landscape

The autoimmune treatment market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Amgen, Johnson & Johnson, Eli Lilly & Co., Pfizer, Roche, Astrazeneca Plc, Bristol-Myers Squibb Co. GlaxoSmithKline Plc, and Lupin Limited among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the autoimmune treatment market globally.

Amgen Inc

  • Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
  • Product Portfolio: The Company's portfolio comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.

Why Purchase the Report?

  • Visualize the composition of the autoimmune treatment market segmentation by drug class, indication, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in autoimmune treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of autoimmune treatment market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global autoimmune treatment market report would provide an access to an approximately 45+ market data table, 40+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Autoimmune Treatment Market - By Drug Class

  • Anti-Inflammatory
  • Anti-Hyperglycemic
  • NSAIDs
  • Interferons
  • Other

Global Autoimmune Treatment Market - By Indication

  • Rheumatic Disease
  • Diabetes
  • Multiple Sclerosis
  • Inflammatory Bowel Disease
  • Other

Global Autoimmune Treatment Market - By Distribution Channel

  • Hospital Pharmacy
  • Pharmacy Stores
  • Other

Global Autoimmune Treatment Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Table of Contents
Product Code: DMPH4058

Table of Contents

1. Global Autoimmune Treatment Market - Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Autoimmune Treatment Market - Market Definition and Overview

3. Global Autoimmune Treatment Market - Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market snippet by Indication
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Autoimmune Treatment Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Prevalence of Autoimmune Diseases
      • 4.1.1.2. Increasing Investments in Research and development
    • 4.1.2. Restraints:
      • 4.1.2.1. Higher Cost of Therapeutics
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Autoimmune Treatment Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Autoimmune Treatment Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Autoimmune Treatment Market - By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    • 7.1.2. Market Attractiveness Index, By Drug Class Segment
  • 7.2. Anti-Inflammatory *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Anti-Hyperglycemic
  • 7.4. NSAIDs
  • 7.5. Interferons
  • 7.6. Other

8. Global Autoimmune Treatment Market - By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Rheumatic Disease *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Diabetes
  • 8.4. Multiple Sclerosis
  • 8.5. Inflammatory Bowel Disease
  • 8.6. Other

9. Global Autoimmune Treatment Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Pharmacy Stores
  • 9.4. Other

10. Global Autoimmune Treatment Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6.
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Autoimmune Treatment Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Autoimmune Treatment Market- Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Amgen
  • 12.3. Johnson & Johnson
  • 12.4. Eli Lilly & Co.
  • 12.5. Pfizer
  • 12.6. Roche
  • 12.7. Astrazeneca Plc
  • 12.8. Bristol-Myers Squibb Co.
  • 12.9. GlaxoSmithKline Plc
  • 12.10. Lupin Limited.

LIST NOT EXHAUSTIVE

13. Global Autoimmune Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us